NAMSNewAmsterdam Pharma Company N.V.
$19.70-46% 1Y
$19.70
$19.7052 weeks$41.45
Latest close: a new 52-week lowOct 23, 2026what changed →
Is the business good?
Mixed
1 neutral, 3 without dataMargins steady. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Margin direction, 3 yearsStablederived
Margins have held roughly steady, a stable cost structure.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is NAMS?
NewAmsterdam Pharma Company N.V. spent more than it took in: an operating loss of $244M on $7.1M of revenue, 12 months to Q2 2026.
$244M
Operating loss · on $7.1M of revenue · 12 months to Q2 2026
- Share count, year on year
- +4.1%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2022 | −3.5% |
| FY2023 | −1299% |
| FY2024 | −387% |
| FY2025 | −1003% |
Details›
- Operating margin12 months to Q2 2026
- −3432%
- Net margin12 months to Q2 2026
- −3644%
- Free cash flow margin
- −2018%
- R&D as % of revenue
- 2096%
- Revenue, trailing twelve months
- $7.1M
- Free cash flow, trailing twelve months
- −$144M
- Net income, trailing twelve months
- −$260M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.